Haizheng Pharmaceutical announced that the company signed a patented technology platform and product licensing cooperation agreement with Suzhou Xuanjing Biotech and its wholly-owned subsidiary to introduce a patented technology platform for small nucleic acid development and RGN6669 products in the early pre-clinical development stage to obtain global rights and exclusive development, registration, production and commercialization rights for cooperative products. The agreement agreed that the initial payment would be 10 million yuan, the cumulative development milestone payment would not exceed 348 million yuan, and the cumulative sales milestone payment would not exceed 630 million yuan; the bill has been reviewed and passed by the board of directors and still needs to be submitted to the 2026 Fourth Extraordinary General Meeting of Shareholders for consideration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.